AskBio recently started a phase 2 trial of AB-1002, called GenePHIT, that will compare two doses of AB-1002 to placebo in around 150 patients with NYHA Class III heart failure, with a primary analysis …
Read Full Story at source (may require registration)
Latest posts by CHF Editor (see all)
- Technical talk: EUR/CHF rejecting monthly resistance - January 24, 2024
- USD/CHF moves higher to near 0.8680 as Fed members maintain a hawkish stance - January 24, 2024
- Holcim price target lowered by CHF 2 at Barclays - January 24, 2024